Grail
E474924
Grail is a biotechnology company focused on developing blood-based tests for early cancer detection using advanced genomic sequencing and data science.
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
cancer diagnostics company ⓘ |
| acquiredBy | Illumina NERFINISHED ⓘ |
| aimsTo |
enable multi-cancer screening from a single blood draw
ⓘ
integrate cancer screening into routine care ⓘ |
| analyzes |
cell-free DNA
ⓘ
methylation patterns ⓘ |
| collaboratesWith |
health systems
ⓘ
research institutions ⓘ |
| countryOfHeadquarters |
United States of America
ⓘ
surface form:
United States
|
| dataApproach |
large-scale clinical data analysis
ⓘ
population-scale studies ⓘ |
| detects |
cancer signals in blood
ⓘ
multiple cancer types ⓘ |
| focusesOn |
blood-based cancer screening tests
ⓘ
early cancer detection ⓘ liquid biopsy ⓘ |
| foundedBy | Illumina NERFINISHED ⓘ |
| goal |
detect cancer at early stages
ⓘ
reduce cancer mortality ⓘ |
| hasMajorInvestor |
Amazon-related investment entities
ⓘ
Arch Venture Partners NERFINISHED ⓘ Bill Gates NERFINISHED ⓘ Jeff Bezos NERFINISHED ⓘ Johnson & Johnson Innovation NERFINISHED ⓘ |
| headquartersLocation | Menlo Park, California, United States NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
medical diagnostics ⓘ |
| market |
cancer screening
ⓘ
oncology diagnostics ⓘ |
| product | Galleri NERFINISHED ⓘ |
| productType | multi-cancer early detection test ⓘ |
| regulatoryEnvironment | subject to FDA oversight ⓘ |
| researchArea |
cancer genomics
ⓘ
circulating tumor DNA ⓘ epigenetics ⓘ oncology ⓘ |
| spinOffFrom | Illumina NERFINISHED ⓘ |
| testType | blood test ⓘ |
| usesMethod |
pattern recognition in genomic data
ⓘ
statistical modeling of cancer signals ⓘ |
| usesTechnology |
bioinformatics
ⓘ
data science ⓘ genomic sequencing ⓘ machine learning ⓘ next-generation sequencing ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.